Brokers Issue Forecasts for ARWR FY2028 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Stock analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a report issued on Wednesday, July 1st. HC Wainwright analyst P. Trucchio anticipates that the biotechnology company will post earnings of ($3.18) per share for the year. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.00) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ FY2029 earnings at ($1.09) EPS and FY2030 earnings at $3.06 EPS.

Several other equities research analysts also recently weighed in on ARWR. Leerink Partners increased their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a report on Wednesday, June 17th. Chardan Capital reaffirmed a “buy” rating and issued a $90.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday. Wall Street Zen upgraded shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Sanford C. Bernstein raised their price objective on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings lowered shares of Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $87.27.

Arrowhead Pharmaceuticals Trading Up 4.4%

ARWR opened at $83.99 on Friday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 1.41. Arrowhead Pharmaceuticals has a 52 week low of $14.30 and a 52 week high of $84.55. The business’s 50 day moving average is $76.57 and its two-hundred day moving average is $68.67. The firm has a market cap of $11.83 billion, a price-to-earnings ratio of -39.06 and a beta of 1.26.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.10) by $0.17. The firm had revenue of $73.74 million during the quarter, compared to analysts’ expectations of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business’s revenue was down 86.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.75 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in ARWR. Versant Capital Management Inc increased its holdings in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 248 shares in the last quarter. Pacer Advisors Inc. purchased a new position in Arrowhead Pharmaceuticals during the first quarter worth $1,500,000. Empowered Funds LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 661.6% in the first quarter. Empowered Funds LLC now owns 137,220 shares of the biotechnology company’s stock worth $8,604,000 after acquiring an additional 119,202 shares during the last quarter. Pine Valley Investments Ltd Liability Co lifted its position in shares of Arrowhead Pharmaceuticals by 1.8% in the first quarter. Pine Valley Investments Ltd Liability Co now owns 18,814 shares of the biotechnology company’s stock valued at $1,180,000 after acquiring an additional 335 shares in the last quarter. Finally, Parallel Advisors LLC lifted its position in shares of Arrowhead Pharmaceuticals by 407.1% in the first quarter. Parallel Advisors LLC now owns 1,004 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 806 shares in the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Buying and Selling

In other news, CFO Daniel Joseph Apel sold 13,095 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer directly owned 162,905 shares in the company, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Hongbo Lu sold 2,970 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the sale, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This trade represents a 5.40% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 26,065 shares of company stock valued at $1,912,662. Corporate insiders own 3.60% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.